Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-epileptic Drug Treatment in Children With Refractory Seizures
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized study designed to compare long-term treatment outcomes in pediatric patients with refractory seizures treated with VNS (Vagus Nerve Stimulation) Therapy versus anti-epileptic drugs (AEDs). Seizure reduction, quality of life measures, and side effect profiles will be evaluated. The results of this study will provide controlled comparative data to better guide physicians in determining the best overall treatment strategy for patients with seizures who have failed initial AED therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Epilepsy |
Other: Anti-epileptic drug (AED) therapy Device: Vagus Nerve Stimulation (VNS) Therapy |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open Randomised Trial to Assess the Efficacy and Safety of Adjunctive Vagus Nerve Stimulation (VNS) Versus Adjunctive New Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures |
- Proportion of Responders [ Time Frame: 1 year ] [ Designated as safety issue: No ]The primary efficacy endpoint is the proportion of responders after one year of follow-up. Responders are defined as patients who have no new anti-epileptic drugs (AEDs) added or significant dose changes in baseline AEDs within one year of follow-up, along with a reduction in the percentage change in seizure frequency from baseline to the one month period prior to the one year follow-up of at least 50%.
- Percent change in seizure frequency [ Time Frame: 1 year ] [ Designated as safety issue: No ]Percent change in seizure frequency in patients who were previously treated with 2 to 5 anti-epileptic drugs (AEDs) versus patients previously treated with more then 5 AEDs.
- Quality of Life in Epilepsy (QOLIE-31) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
To compare adjunctive Vagus Nerve Stimulation (VNS) treatment using the VNS Therapy device to adjunctive anti-epileptic drug (AED) treatment in improving the quality of life of patients with seizures.
The Quality of Life in Epilepsy Inventory (QOLIE-31) contains seven multi-item scales that tap the following health concepts: emotional well being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life. Scores range from 0-100 with higher values indicating greater quality of life.
- Adverse Event Profile [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]To compare the safety of adjunctive Vagus Nerve Stimulation (VNS) treatment using the VNS Therapy device to adjunctive anti-epileptic drug (AED) therapy in treating patients with seizures
| Enrollment: | 151 |
| Study Start Date: | October 2004 |
| Study Completion Date: | February 2010 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vagus Nerve Stimulation (VNS) Therapy
Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
|
Device: Vagus Nerve Stimulation (VNS) Therapy
Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
|
| Active Comparator: Anti-epileptic drug (AED) therapy | Other: Anti-epileptic drug (AED) therapy |
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Refractory seizures
- Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose;
- Having at least 3 appropriate AEDs left to try
- Having his/her current AED medication at an optimal dose at baseline
- At least three seizures per month (average over 2 months prior to admission), excluding absences.
- No more than four (4) weeks between seizures (over 2 months prior to admission)
- Age 17 years or less
- Having been evaluated for epilepsy surgery and resective surgery not felt indicated or patient/parents/legal guardian declined.
- Patient is a male or patient is a nonpregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control. Abstinence is an acceptable means of birth control
- Patient or legal guardian understands study procedures and has voluntarily signed an informed consent in accordance with institutional policies.
Exclusion Criteria:
- Having tried less then 2 AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal doses in the patient's lifetime
- A progressive neurological condition (e.g. brain tumor etc.)
- Inability of the parents or reluctance of the child to comply with the frequency of clinic visits during the treatment phase
- Patient has a history of noncompliance for seizure diary completion.
- Patient has taken an investigational drug within a period of five times the mean elimination half-life of the investigational drug plus two weeks.
- Patient is currently using another investigational device or drug.
- Patient is likely to require a whole body Magnetic resonance imaging (MRI) after VNS Therapy device implantation. (Refer to the Physician's Manual for the NCP Generator for additional information on the use of MRI.)
- Patient is currently receiving or likely to receive short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy after implantation (Refer to Physician's Manual for the VNS (Vagus Nerve Stimulation) Therapy device for additional information on the contraindicated use of diathermy).
- Patient was previously enrolled in this or any other VNS Therapy device Study.
- Patient has an active peptic ulcer
- Patient has another unstable medical condition likely to precipitate seizures and make it difficult to evaluate to evaluate efficacy (e.g. diabetes)
- Patient has had a unilateral or bilateral cervical vagotomy.
- Patient is pregnant at the time of enrolment.
Contacts and Locations| Austria | |
| Medical University of Vienna - Vienna General Hospital (AKH) | |
| Vienna, Austria | |
| Belgium | |
| CUB Hôpital Erasme | |
| Brussels, Belgium | |
| Germany | |
| Kinderklinik der Justus-Liebig Universität | |
| Giessen, Germany | |
| University of Lübeck - Clinic for Paediatric Medicine | |
| Lübeck, Germany | |
| Sweden | |
| University Hospital Lund | |
| Lund, Sweden | |
| University Children's Hospital | |
| Uppsala, Sweden | |
| United Kingdom | |
| Birmingham Children's Hospital | |
| Birmingham, United Kingdom | |
| Royal Hospital for Sick Children | |
| Bristol, United Kingdom | |
| Addenbrookes Hospital | |
| Cambridge, United Kingdom | |
| Leeds General Infirmary | |
| Leeds, United Kingdom | |
| Great Ormond Street Hospital for Children | |
| London, United Kingdom | |
| Kings College Hospital | |
| London, United Kingdom | |
| Royal Manchester Children's Hospital | |
| Manchester, United Kingdom | |
| Sir James Spence Institute - Royal Victoria Infirmary | |
| Newcastle, United Kingdom | |
| Queens's Medical Centre Nottingham | |
| Nottingham, United Kingdom | |
| Sheffield Children's Hospital | |
| Sheffield, United Kingdom | |
| Southampton Hospital | |
| Southampton, United Kingdom | |
| Study Director: | Mark Bunker, PharmD | Cyberonics, Inc. |
More Information
No publications provided
| Responsible Party: | Mark Bunker, PharmD, Sr. Director, Global Medical Affairs, Cyberonics, Inc |
| ClinicalTrials.gov Identifier: | NCT01118455 History of Changes |
| Other Study ID Numbers: | E-06 |
| Study First Received: | May 5, 2010 |
| Last Updated: | May 5, 2010 |
| Health Authority: | United Kingdom: Research Ethics Committee Belgium: Institutional Review Board Sweden: Institutional Review Board Germany: Ethics Commission Austria: Ethikkommission |
Additional relevant MeSH terms:
|
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013